高好考,陈根锐,李成祥

• 1:空军军医大学第一附属医院心血管内科

摘要(Abstract)：

<正>1临床资料患者男,53岁。主因"反复胸闷、气短4个月,加重1周"于2019年2月入住空军军医大学第一附属医院。4个月前无明显诱因出现胸闷、气短,夜间频繁,1周前加重伴有夜间阵发性呼吸困难。当地医院就诊行冠状动脉造影示:左主干全程病变,累及末段分叉部,最严重部位70%狭窄;左前降支(left anterior descending coronary artery,LAD)近段80%狭

关键词(KeyWords)： 左心室辅助装置;经皮冠状动脉介入治疗;冠心病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 高好考,陈根锐,李成祥

参考文献(References)：

• [1] Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care(endor sed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion;Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention). J Card Fail,2015,21(6):499-518.
• [2]中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016).中华心血管病杂志,2016,44(5):382-400.
• [3] Minha S, Barbash IM, Dvir D, et al. Correlates for mortality in patients presented with acute myocardial infarct complicated by cardiogenic shock. Cardiovasc Revasc Med, 2014, 15(1):13-17.
• [4] Bagai J, Webb D, Kasasbeh E, et al. Efficacy and safety of percutaneous life support during high-risk percutaneous coronary intervention, ref ractory cardiogenic shock and in-laboratory cardiopulmonary arrest. J Invasive Cardiol,2011,23(4):141-147.
• [5] Tsao NW, Shih CM, Yeh JS, et al. Extracorporeal membrane oxygenation-assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock. J Crit Care, 2012, 27(5):530.e1-e11.
• [6] Goyal D, Nadar SK, Wrigley B, et al. Successful use of intra-aortic counter pulsation therapy for intractable ventricular arrhythmia in patient with severe left ventricular dysfunction and normal coronary arteries. Cardiol J, 2010, 17(4):401-403.
• [7] Gregoric ID, Bruckner BA, Jacob L, et al. Techniques and complications of TandemHeart ventricular assist device insertion during cardiac procedures. ASAIO J, 2009, 55(3):251-254.
• [8] Meyns B, Dens J, Sergeant P, et al. Initial experiences with the Impella device in patients with cardiogenic shock-Impella support for cardiogenic shock. Thorac Cardiovasc Surg, 2003, 51(6):312-317.
• [9] Dixon SR, Henriques JP, Mauri L, et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention(The PROTECT I Trial):initial U. S. experience. JACC Cardiovasc Interv, 2009, 2(2):91-96.
• [10] Sjauw KD, Konorza T, Erbel R, et al. Supported high-risk percutaneous coronary intervention with the Impella 2. 5 device the Europella registry. J Am Coll Cardiol, 2009, 54(25):2430-2434.
• [11] Harmon L, Boccalandro F. Cardiogenic shock secondary to severe acute ischemic mitral regurgitation managed with an Impella 2.5percutaneous left ventricular assist device. Catheter Cardiovasc Interv,2012, 79(7):1129-1134.
• [12] Froesch P, Martinelli M, Meier P, et al. Clinical use of temporary percutaneous left ventricular assist devices. Catheter Cardiovasc Interv, 2011, 78(2):304-313.
• [13] Dangas GD, Kini AS, Sharma SK, et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneouscoronary intervention(from the PROTECT II randomized trial). Am J Cardiol, 2014, 113(2):222-228.